Seattle Genetics (SGEN) Misses Q1 EPS by 19c, Revenues Miss; Maintains FY20 Sales Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics Reports First Quarter 2020 Financial Results
April 30, 2020 4:02 PM EDT-ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $164.1 Million in the First Quarter, an Increase of 22 percent Over the First Quarter of 2019-
-PADCEV (Enfortumab Vedotin-efjv) Net Sales in U.S. Reach $34.5 Million in First Full Quarter of Commercialization-
-TUKYSA (Tucatinib) Approved by FDA for Patients with HER2-Positive Metastatic Breast Cancer Who Have Received One or More Prior Anti-HER2 Regimens in the Metastatic Setting-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle... More
